According to FutureWise analysis the market for immunoglobulins in 2025 is US$ 15.69 billion, and is expected to reach US$ 27.07 billion by 2033 at a CAGR of 7.53%.
Immunoglobulins are known as glycoproteins which are formed in the blood plasma. This, in turn, reacts to antigens that are in the body. Intravenous immunoglobulin is a blood product which is arranged from the serum and accounts to nearly 1,000 to 10,000 donors per donor. Such immunoglobulins are administered to people who are afflicted with weak immune systems. An illness such as immunodeficiency could be inherent in the body or could be attributed to the exposure of infections, by way of bodily fluids as well as chemotherapy and cancer drugs. The aging process could be another factor and can even make a person susceptible to a poor immune system.
Fast-paced and unbalanced lifestyles have led people to take to unhealthy diets and this, in turn, has caused them to develop weak immune systems. Attributes such as reduced sleeping patterns, high levels of stress, and unhealthy diets are factors which are contributing to the ever-growing presence of the illness known as immunodeficiency disorder.
Treatment of this nature is used for patients who are afflicted with antibody deficiencies. The global market for geriatric population has gained a strong foothold since there is an exponential rise in the number of hemophilic patients, technological prowess for the boost in production of intravenous immunoglobulin and positive strides in the purification methodologies. Although, stringent government guidelines with respect to the detrimental side-effects of intravenous immunoglobulin could hamper the global immunoglobulins market growth.
Going by the segmentation of component, the market for immunoglobulin is divided into IgA, IgD, IgM, IgG, IgE. The rise in the patient pool and a multitude of neurological disorders are prompting the need for speedy and dependable treatment and these are factors which have contributed significantly towards the usage of intravenous immunoglobulin in the treatment of unlabeled indications. To add to this, a hike in the research and development investments for novel goods from private and government officiated organizations alike, are expected to further augment the global immunoglobulins market size. Application-wise, the market is fragmented into Guillain-Barre syndrome, CIDP (chronic inflammatory demyelinating polyneuropathy), myasthenia gravis, immunodeficiency diseases, inflammatory myopathies, hypogammaglobinemia, thrombocytopenic purpura, specific antibody deficiency, multifocal motor neuropathy and others.